Loading clinical trials...
Loading clinical trials...
A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Cancer
Conditions
Interventions
Cyclophosphamide
Epirubicin Hydrochloride
+4 more
Locations
115
United States
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
Eden Hospital Medical Center
Castro Valley, California, United States
Marin Cancer Care Inc
Greenbrae, California, United States
Saint Rose Hospital
Hayward, California, United States
Valley Care Health System - Pleasanton
Pleasanton, California, United States
Valley Medical Oncology Consultants
Pleasanton, California, United States
Start Date
July 1, 2007
Primary Completion Date
June 1, 2012
Completion Date
February 21, 2013
Last Updated
January 23, 2019
NCT06324240
NCT05452681
NCT01570998
NCT04001829
NCT05455658
NCT02276443
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions